Specifically, Dupixent is approved to treat moderate to severe asthma that is either: dependent on treatment with an oral corticosteroid, or eosinophilic (caused by an increase in eosinophils ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products ...

Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis ... to be a first- and ...

Analyst Chris Schott from J.P. Morgan maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at ...